Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer

Late breast cancer recurrence



Breast cancer, Recurrence, Survival, Hormonotherapy


Background/Aim: Over the years, disease-free survival (DFS) has been considerably prolonged with effective treatments in resectable breast cancer patients. However, a limited number of studies evaluating the predictive and prognostic factors of the disease in breast cancer patients who develop late recurrence are available. In this respect, we investigated clinicopathological features and risk factors affecting the survival of patients who developed breast cancer recurrence (BCR) after 60 months (late BCR).

Methods: In this retrospective cohort study, clinicopathological features and survival outcomes of 45 late BCR patients were evaluated. The demographic and medical data of the patients were obtained from the retrospective registry system of our center. Statistical analyses were performed to determine the risk factors affecting DFS.

Results: The median age of the cohort was 49 (24–78) years. Twenty-three postmenopausal patients were included in the study, and the mean age of menopause was 50 (43–55) years. Fourteen (31.1%) patients were stage 3 at diagnosis. In the adjuvant period, 80% of the patients underwent radiotherapy, and 79.5% underwent chemotherapy. The mean duration of adjuvant hormone therapy was 64 (69–129) months. Adjuvant ovarian suppression therapy was applied to 14 patients. The three most common sites of recurrence were bones (57.8%), locoregional (26.7%), and distant lymph nodes (26.7%). The median DFS of the cohort was 116.9 (3.7) months (109.6–124.1 months). Disease-related deaths occurred in only five patients, and the median overall survival (OS) could not be achieved. Based on a log-rank analysis, the median DFS was longer in patients whose adjuvant hormone therapy duration was 5–10 years and in those with bone or lymph node recurrence (P = 0.025 and P = 0.001, respectively). DFS was significantly shorter in patients with liver metastases (P = 0.005). Based on a chi-squared analysis, bone and lymph node metastases were higher in luminal A-like group (P = 0.030), and liver metastasis was lower (P = 0.039). Luminal biology did not affect late BCR (P = 0.075).

Conclusions: Prolonged adjuvant hormone therapy (5–10 years) delays breast cancer recurrence. However, luminal features are insufficient to predict recurrence as the recurrence period increases. In addition, different sites of metastases are associated with long-term survival and luminal subgroups.


Download data is not yet available.


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30. doi: 10.3322/caac.21442. PubMed PMID: 29313949. DOI: https://doi.org/10.3322/caac.21442

Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The Lancet Oncology. 2008;9(8):730-56. doi: 10.1016/S1470-2045(08)70179-7. PubMed PMID: 18639491. DOI: https://doi.org/10.1016/S1470-2045(08)70179-7

Washbrook E. Risk factors and epidemiology of breast cancer. Women's Health Medicine. 2006;3(1):8-14. doi: 10.1383/wohm.2006.3.1.8. DOI: https://doi.org/10.1383/wohm.2006.3.1.8

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67(1):7-30. doi: 10.3322/caac.21387. PubMed PMID: 28055103. DOI: https://doi.org/10.3322/caac.21387

Jung S, Wang M, Anderson K, Baglietto L, Bergkvist L, Bernstein L, et al. Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. Int J Epidemiol. 2016;45(3):916-28. doi: 10.1093/ije/dyv156. PubMed PMID: 26320033; PubMed Central PMCID: PMC5005939. DOI: https://doi.org/10.1093/ije/dyv156

Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165(1):193-200. doi: 10.1007/s10549-017-4325-2. PubMed PMID: 28578505; PubMed Central PMCID: PMC5511313. DOI: https://doi.org/10.1007/s10549-017-4325-2

Wörmann B. Breast cancer: basics, screening, diagnostics and treatment. Medizinische Monatsschrift fur Pharmazeuten. 2017;40(2):55-64. Epub 2017/02/01. PubMed PMID: 29952495.

Brandt J, Garne JP, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. World journal of surgical oncology. 2015;13(1):1-11. DOI: https://doi.org/10.1186/s12957-014-0429-x

Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046-52. doi: 10.1038/sj.bjc.6602787. PubMed PMID: 16175185; PubMed Central PMCID: PMC2361680. DOI: https://doi.org/10.1038/sj.bjc.6602787

Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349-53. doi: 10.1007/s10549-006-9301-1. PubMed PMID: 17009109. DOI: https://doi.org/10.1007/s10549-006-9301-1

Orvieto E, Maiorano E, Bottiglieri L, Maisonneuve P, Rotmensz N, Galimberti V, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer. 2008;113(7):1511-20. doi: 10.1002/cncr.23811. PubMed PMID: 18704988. DOI: https://doi.org/10.1002/cncr.23811

Ferlicot S, Vincent-Salomon A, Medioni J, Genin P, Rosty C, Sigal-Zafrani B, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. European journal of cancer (Oxford, England : 1990). 2004;40(3):336-41. PubMed PMID: 14746850. DOI: https://doi.org/10.1016/j.ejca.2003.08.007

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine. 2018;379(2):122-37. doi: 10.1056/NEJMoa1803164. PubMed PMID: 29863451. DOI: https://doi.org/10.1056/NEJMoa1803164

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet (London, England). 2013;381(9869):805-16. Epub 2012/12/12. doi: 10.1016/s0140-6736(12)61963-1. PubMed PMID: 23219286; PubMed Central PMCID: PMCPMC3596060.

Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. American Society of Clinical Oncology; 2013. DOI: https://doi.org/10.1200/jco.2013.31.18_suppl.5

Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. The Lancet Oncology. 2017;18(11):1502-11. Epub 2017/10/17. doi: 10.1016/s1470-2045(17)30600-9. PubMed PMID: 29031778. DOI: https://doi.org/10.1016/S1470-2045(17)30600-9

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute. 2018;110(1). Epub 2017/09/20. doi: 10.1093/jnci/djx134. PubMed PMID: 28922787. DOI: https://doi.org/10.1093/jnci/djx134

Mamby CC, Love RR, Heaney E. Metastatic breast cancer 39 years after primary treatment. Wisconsin medical journal. 1993;92(10):567-9.

Lakhani SR, Ellis IO, Schnitt S, Tan PH, van de Vijver M. WHO Classification of Tumours of the Breast. 2012.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10. Epub 1991/11/01. doi: 10.1111/j.1365-2559.1991.tb00229.x. PubMed PMID: 1757079. DOI: https://doi.org/10.1111/j.1365-2559.1991.tb00229.x

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(16):2784-95. Epub 2010/04/21. doi: 10.1200/jco.2009.25.6529. PubMed PMID: 20404251; PubMed Central PMCID: PMCPMC2881855 are found at the end of this article.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(8):1533-46. Epub 2015/05/06. doi: 10.1093/annonc/mdv221. PubMed PMID: 25939896; PubMed Central PMCID: PMCPMC4511219.

Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. JNCI: Journal of the National Cancer Institute. 2021;114(3):391-9. doi: 10.1093/jnci/djab202. DOI: https://doi.org/10.1093/jnci/djab202

Derks MG, Blok EJ, Seynaeve C, Nortier JW, Kranenbarg EM-K, Liefers G-J, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2017;18(9):1211-20. doi: 10.1016/S1470-2045(17)30419-9 DOI: https://doi.org/10.1016/S1470-2045(17)30419-9

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al. Factors predicting late recurrence for estrogen receptor–positive breast cancer. Journal of the National Cancer Institute. 2013;105(19):1504-11. doi: 10.1093/jnci/djt244 DOI: https://doi.org/10.1093/jnci/djt244

Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast Cancer Subtypes Predispose the Site of Distant Metastases. American Journal of Clinical Pathology. 2015;143(4):471-8. doi: 10.1309/ajcpyo5fsv3upexs. DOI: https://doi.org/10.1309/AJCPYO5FSV3UPEXS

Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer management and research. 2018;10:5329-38. Epub 2018/11/23. doi: 10.2147/cmar.s176763. PubMed PMID: 30464629; PubMed Central PMCID: PMCPMC6225920. DOI: https://doi.org/10.2147/CMAR.S176763

Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Oncology. 2018;2(1):4. doi: 10.1038/s41698-018-0047-0. DOI: https://doi.org/10.1038/s41698-018-0047-0

Wyld L, Gutteridge E, Pinder S, James J, Chan S, Cheung K, et al. Prognostic factors for patients with hepatic metastases from breast cancer. British journal of cancer. 2003;89(2):284-90. doi: 10.1038/sj.bjc.6601038. DOI: https://doi.org/10.1038/sj.bjc.6601038






Research Article

How to Cite

Ferhatoğlu F, Aydiner A, Paksoy N. Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer: Late breast cancer recurrence. J Surg Med [Internet]. 2022 Dec. 23 [cited 2024 Apr. 23];6(12):986-90. Available from: https://jsurgmed.com/article/view/7610